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Abstract That signalling pathways, particularly the mitogen-
activated protein kinase cascades, elicit modi¢cation of chroma-
tin proteins such as histone H3 by phosphorylation and/or ace-
tylation concomitant with gene activation is now well estab-
lished. The picture that is emerging is one of a complex and
dynamic pattern of multiple modi¢cations at the H3 tail. Here,
we review the inducible gene systems where H3 modi¢cations
have been reported and re-evaluate the controversy as to the
kinase(s) that phosphorylates it as well as the proposed coupling
between H3 phosphorylation and acetylation.
# 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
When cells receive external signals initiated by growth fac-
tors, cytokines, pharmacological agents or stresses, intracellu-
lar signalling pathways are activated which rapidly alter pat-
terns of gene expression. The ¢rst phase of this is the
induction of immediate-early (IE) genes, those that are di-
rectly connected to intracellular signalling systems and do
not require new protein synthesis. Much emphasis and re-
search e¡ort in the signal transduction ¢eld has focused on
identifying the physiologically relevant targets of such path-
ways, particularly the transcription factors and co-activators
at the enhancers and promoters of individual genes. More
recently, it has become clear that chromatin structure plays
an important role in eukaryotic gene regulation. An increasing
body of evidence indicates that as well as directing the phos-
phorylation of upstream transcription factors and co-activa-
tors controlling IE genes, signalling pathways, particularly the
mitogen-activated protein (MAP) kinase cascades, also act
directly on chromatin proteins such as histone H3 and high
mobility group HMG-14 (HMGN1 revised nomenclature [1])
to modify chromatin concomitant with gene induction.
Alterations in chromatin structure can be achieved by two
main mechanisms: the post-translational modi¢cation of his-
tones in their amino-terminal tails by acetylation, phosphor-
ylation, methylation and ubiquitination (see [2] for a review
and references therein), or remodelling of nucleosomes via the
ATP-dependent chromatin remodelling complexes such as
Swi/Snf (see [3^5] for reviews). Chromatin remodelling com-
plexes are not within the scope of this review. Post-transla-
tional histone modi¢cations may a¡ect chromatin structure by
altering histone^DNA contacts. The modi¢cations (or combi-
nations of modi¢cations) may also act as binding platforms/
recognition motifs for interaction with other proteins that
may provide further enzyme activity or recruit additional reg-
ulatory proteins, as proposed by the histone code hypothesis
[6^8]. So far, two types of speci¢c protein domains, the bro-
modomain that binds to acetyl-lysine (reviewed in [9,10]) and
the chromodomain that binds to methyl-lysine (reviewed in
[11]) have been identi¢ed.
Acetylation has been the most extensively studied modi¢ca-
tion and the ¢rst indications that inducible genes may exhibit
enhanced acetylation upon activation came from the work of
Allfrey and colleagues looking at the c-fos and c-myc genes
[12,13]. More recently, phosphorylation of histone H3 con-
comitant with IE gene induction has been demonstrated
[14], and the MAP kinase cascades that deliver this response
have been elucidated [15^17]. These studies eventually led to
the remarkable demonstration that both modi¢cations were
targeted to the same histone H3 tails and that these were
directly located on IE gene chromatin [18^20]. Here, we re-
view the di¡erent inducible gene systems where histone H3
phosphorylation and acetylation have been reported, re-eval-
uate the controversy as to the kinase that phosphorylates it
and ¢nally, discuss the proposed coupling between the two
modi¢cations.
2. Nucleosome modi¢cations induced by extracellular stimuli
Extracellular stimuli are connected to IE genes by several possible
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signalling pathways. These include the Janus kinase/signal transducer
and activator of transcription (JAK/STAT) signalling pathway (re-
viewed in [21]), the nuclear factor UB (NF-UB) pathway (reviewed in
[22]) and the MAP kinase signalling pathways (reviewed in [23,24]).
We will concentrate mainly on MAP kinase-mediated signalling to
chromatin since this is one of the most extensively studied systems
to date, in particular with respect to histone H3 modi¢cations.
The main experimental models for inducible phosphorylation and
acetylation of histone H3 linked to activation of inducible genes have
been the c-jun and c-fos proto-oncogene families [18^20,25,26]. These
genes are activated rapidly and transiently, without a requirement for
new protein synthesis, and are therefore linked directly to signalling
cascades. Present indications are that these genes are under tight
quantitative control, induction being highly characteristic and repro-
ducible in terms of the extent and duration of expression in response
to di¡erent stimuli (reviewed in [27]).
3. MAP kinase pathways
There are currently four MAP kinase cascades that are
di¡erentially activated depending on stimulus: (1) the extra-
cellular signal-regulated kinase/mitogen-activated protein ki-
nase (ERK/MAPK) 1/2 pathway, (2) the c-Jun amino-termi-
nal kinase/stress-activated protein kinase (JNK/SAPK)
pathway, (3) the p38 pathway and (4) the big mitogen-acti-
vated protein kinase BMK/ERK 5 pathway (shown schemati-
cally in Fig. 1). The signalling network leading to activation
of the MAP kinases themselves and some of their downstream
targets has been extensively reviewed elsewhere (see [27] and
references therein).
Activation of the MAP kinase pathways leads ultimately to
the phosphorylation of transcription factors bound to their
regulatory elements in the promoters of target genes.
Phosphorylation of these transcription factors is crucial for
gene activation [28], but it is now clear that upstream elements
and transcription factors can also direct acetylation to nucle-
osomes of IE gene chromatin. Co-activators such as p300/
CBP are histone acetyltransferases (HATs) [29,30] that bind
to a variety of transcription factors such as c-Jun and c-Fos
(see [31] and references therein). CBP itself can then recruit
further HAT activity by association with p/CAF [32]. The
MAP kinase-dependent recruitment of co-activators with
HAT activity to sequence-speci¢c regulatory elements pro-
vides a possible mechanism for the targeted localised altera-
tions in histone acetylation levels that have been observed in a
number of di¡erent systems [33^40].
4. Histone H3 phosphorylation
Serines 10 and 28 on the histone H3 tail are both preceded
by the same three amino acids (alanine-arginine-lysine) and
both these phosphorylatable motifs are very highly conserved
through evolution, being identical in yeast and man. There are
two distinct modes of histone H3 phosphorylation, mitotic
Fig. 1. Schematic representation of the four characterised mammalian MAP kinase cascades and target substrates including downstream ki-
nases, transcription factors and nucleosomal proteins, modi¢ed from [27]. The four cascades are the ERK/MAPK pathway, the JNK/SAPK
pathway, the p38/reactivating kinase (RK) pathway, and the BMK/ERK5 pathway. Kinase substrates downstream of the MAP kinases them-
selves are shown as rectangles. Transcription factor substrates are shown as ovals and nucleosomal proteins are shown as octagons. For further
details see [27] and references therein.
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and stimulus-inducible phosphorylation, both of which can
utilise these two serine residues. Currently identi¢ed stimu-
lus-induced and mitotic H3 kinases are summarised in Table 1.
4.1. Mitotic H3 phosphorylation
It has long been observed that serine 10 on histone H3 is
very highly phosphorylated on condensed chromosomes dur-
ing mitosis ([41^44], reviewed in [45]). More recently serine 28
has been identi¢ed as a second site of phosphorylation in
mammals that also occurs during chromosome condensation
at early mitosis [46]. Mitotic phosphorylation of histone H3
on serine 10 is mediated by members of the Aurora kinase
family such as the Ipl1 kinase in yeast and nematodes [47],
Aurora B in Drosophila [48] and Aurora B (and A) kinases in
mammals ([49] and references therein). Aurora B is also im-
plicated in mitotic serine 28 phosphorylation [50]. In in vitro
assays a histone H3 serine 28 kinase activity has also been
detected in yeast whole cell extracts [51]. Mitotic H3 phos-
phorylation is not discussed further here, but the major di¡er-
ences between mitotic and stimulus-induced modes are that
the former is extensively observed throughout condensed
chromosomes, whereas the latter is transient, a¡ects a minute
fraction of nucleosomes and is associated with active genes
(discussed further below).
4.2. Stimulus-induced histone H3 phosphorylation
The ¢rst link between intracellular signalling pathways and
phosphorylation of chromatin-associated proteins came from
32P labelling studies in mouse ¢broblasts. Diverse stimuli, in-
cluding growth factors and protein synthesis inhibitors, all of
which activate MAP kinase cascades, elicit the rapid and tran-
sient phosphorylation of H3 on serine 10 [52] and also HMG-
14 on serine 6 [53], collectively called the nucleosomal re-
sponse. The extent and duration of the nucleosomal response
correlates with IE gene induction suggesting a role for these
modi¢cations in transcriptional activation [31]. The fraction
of H3 that is phosphorylated at the G0/G1 transition is minute
and is also highly susceptible to hyperacetylation induced by
histone deacetylase (HDAC) inhibitors such as butyrate [14]
and trichostatin A [18]. 32P labelling studies of butyrate-
treated cells [14] provided the ¢rst indication that multiple
modi¢cations (phosphorylation and acetylation) are targeted
to the same histone H3 tail and may be important for IE gene
induction.
A number of systems where inducible H3 phosphorylation
(Ser10) and acetylation is associated with activated inducible
genes have now been reported and are summarised in Table 2.
Furthermore, MAP kinase-mediated phosphorylation of ser-
ine 28, the second site of phosphorylation in the H3 tail,
has also been demonstrated upon stimulation with UV-B
[54,55],12-O-tetradecanoylphorbol 13-acetate (TPA) and ani-
somycin ([56] ; M.H. Dyson and L.C. Mahadevan, unpub-
lished data) and epidermal growth factor (EGF) (M.H. Dyson
and L.C. Mahadevan, unpublished data). We are presently
investigating whether serine 28 phosphorylation is also tar-
geted to IE gene nucleosomes concomitant with gene activa-
tion (M.H. Dyson and L.C. Mahadevan, unpublished data).
No inducible serine 28 phosphorylation has yet been reported
in yeast.
5. MAP kinase-activated histone H3 kinases
The use of relatively speci¢c MAP kinase and other inhib-
itors [57^59] has allowed dissection of the signalling pathways/
mechanisms involved in histone H3 (and HMG-14) phosphor-
ylation in response to diverse stimuli. The ERK pathway is
speci¢cally inhibited by the £avone compound PD098059 and
U0126 compound which inhibit the activation of MEK1/2,
the upstream activator of ERKs [60,61]. The p38 pathway is
inhibited by SB203580, which speci¢cally binds to and inhibits
p38 MAP kinase itself [62]. Studies with such inhibitors have
shown that in mammalian cells H3 (and HMG-14) phosphor-
Table 1
Identi¢ed stimulus-induced and mitotic histone H3 kinases
Species/cells Stimulus Pathway Kinase H3 site Reference
Drosophila melanogaster X dosage compensation ^ JIL-1 Ser10 [75]
Human Co⁄n^Lowry ¢broblasts EGF ERK RSK2 Ser10 [70]
Drosophila melanogaster ^ ^ JIL-1 Ser10 [76]
Mouse C3H 10T1/2 ¢broblasts Arsenite p38 MSK1 Ser10 [87]
Mouse C3H 10T1/2 ¢broblasts sAn p38 MSK1 Ser10 [17]
Mouse JB6 cells UVB p38 ERK JNK MSK1 Ser28 [54]
Rat ovarian granulosa cells FSH PKA PKA Ser10 [77]
NIH 3T3 cells/COS-1 cells EGF ERK RSK2 Ser10 [66]
Saccharomyces cerevisiae Low glucose/sucrose present sip/gal proteins? Snf1 Ser10 [51]
Human promyelocytic leukaemia Arsenite MAPK? MSK1/RSK2? Ser10 [88]
Aspergillus nidulans Mitotic NIMXcdc2 NIMA Ser10 [89]
Caenorhabditis elegans Mitotic ^ AIR-2 Ser10 [47]
Saccharomyces cerevisiae Mitotic ^ Ipl1p Ser10 [47]
Xenopus oocyte Mitotic INCENP? pEg2 Aurora A Ser10 [90]
Drosophila melanogaster Mitotic INCENP Aurora B Ser10 [91]
Human HeLa cells Mitotic cdc2 blocks phosphatase Aurora B Ser28 [50]
Xenopus oocyte Mitotic Loss of pp1 activity? Aurora B Ser10 [92]
Mouse 3T3 Mitotic ^ Aurora B/A Ser10 [49]
Drosophila melanogaster Mitotic ^ Aurora B Ser10 [48]
Human cells Mitotic ^ Nek6 Ser10 [93]
Human MCF-7 breast cancer Mitotic ^ PAK1 Ser10 [94]
Abbreviations: AIR-2, Aurora/Ipl1-related serine/threonine protein kinase 2; ERK, extracellular signal-regulated kinase; FSH, follicle-stimulat-
ing hormone; INCENP, inner centromere protein; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MKP-1, mitogen-
activated protein kinase phosphatase 1; MSK1, mitogen- and stress-activated protein kinase 1; NEK6, NIMA-related expressed kinase 6;
NIMA, Never In Mitosis A; PAK1, p21 activated kinase 1; PKA, protein kinase A; pp1, protein phosphatase 1; RSK2, ribosomal S6
kinase 2; sAn, sub-inhibitory anisomycin.
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ylation (as well as IE gene induction) is mediated via the ERK
or p38 MAP kinase pathways depending on the stimulus used,
but not the JNK/SAPK pathway [15^17]. Although these two
pathways deliver signals to histone H3 and HMG-14, phos-
phorylation is e¡ected by downstream kinases and not by
MAP kinases themselves (see the signalling cascade diagram,
Fig. 1). The subject of much recent contention, two down-
stream kinases, MAP kinase-activated protein kinase-1/ribo-
somal S6-kinase (MAPKAP-K1b/RSK2) and mitogen- and
stress-activated protein kinase (MSK1/2), have been suggested
as the mammalian histone H3/HMG-14 kinases. As discussed
below, recent studies are casting doubt on the physiological
role of RSK2 as the ligand-stimulated H3 kinase. Note that
although the histone H3 phosphorylation sites and MAP ki-
nase cascades are conserved in yeast, the downstream equiv-
alents of these inducible histone H3 kinases are missing, sug-
gesting that this mode of chromatin modi¢cation arose more
recently in evolution.
6. MAPKAP-K1b/RSK2
The MAPKAP-K1/RSKs, of which there are currently four
identi¢ed isoforms in humans, MAPKAP-K1a, b and c, or
RSK1, 2 and 3 (reviewed in [63]) and RSK4 [64], were the
¢rst downstream e¡ector kinases identi¢ed. They are activated
by the ERK pathway and this activation is inhibited by
PD098059 ([65], reviewed in [31]). There are some reports
that UV radiation can lead to phosphorylation and activation
of RSK2 in some cell types [66,67], though the mechanism
remains contentious.
Mutations in one of these kinases, RSK2/MAPKAP-K1b
[68], is found in the human genetic disease Co⁄n^Lowry syn-
drome (CLS). Much of the evidence purporting to show that
RSK2 is a ligand-stimulated H3 kinase comes from studies
using ¢broblasts established from CLS patients. In these cells
only the RSK2 isoform is inactive and EGF-stimulated CREB
phosphorylation and c-fos induction were reported to be de-
fective, although these responses to UV radiation were report-
edly normal [69]. By contrast, stimulation of CLS ¢broblasts
with EGF, serum or UV radiation reportedly failed to pro-
duce a H3 phosphorylation response [70]. Similar results for
EGF-stimulated histone H3 phosphorylation were observed in
mouse embryonic stem cells in which the RSK2 gene was
knocked out by homologous recombination; moreover, trans-
Table 2
Genes associated with stimulus-induced phosphorylation and/or acetylation
Species/cells Stimulus Genes Modi¢cation Reference
Mouse NIH3T3 cells/NIH3T3
SRE-FosHA/SRE-lacZ reporter
cell lines
TPA, sAn serum SRE-fosHA, SRE-lacZ AcH4 [35]
Mouse C3H 10T1/2 ¢broblasts TPA c-fos, c-myc PhosH3 Ser10a [25]
Mouse C3H 10T1/2 ¢broblasts EGF c-fos Phos/AcH3 Ser10/Lys14 [19]
Mouse C3H 10T1/2 ¢broblasts EAn, EGF c-jun, c-fos Phos/AcH3 Lys9/Ser10 [18]
Mouse C3H 10T1/2 ¢broblasts sAn c-jun Phos/AcH3 Lys9/Ser10, AcH3 Lys9
and/or Lys14b, AcH4
[20]
Drosophila salivary glands Heat shock Heat shock loci PhosH3 Ser10a [95]
Rat ovarian granulosa cells FSH SGK, inhibin-K PhosH3 Ser10a [77]
SGK, inhibin-K AcH3 Lys9 and/or Lys14b
SGK, inhibin-K, c-fos Phos/AcH3 Ser10/Lys14
Mouse C3H 10T1/2 ¢broblasts Arsenite MKP1 PhosH3 Ser10a [87]
MKP1, c-fos Phos/AcH3 Ser10/Lys14
Yeast Saccharomyces cerevisiae Inositol starvation INO1 PhosH3 Ser10a, Phos/AcH3
Ser10/Lys14, AcH3 Lys9 and/or
Lys14b
[51]
Mouse P19 embryonal carcinoma cells atRA RAR-L2 PhosH3 Ser10a [96]
Human primary dendritic cells LPS IL-6, IL-8, MCP-1 IL-12p40 PhosH3 Ser10a [84]
Mouse Swiss 3T3 cells sAn and TSA HDAC1c Phos/AcH3 Ser10/Lys14 [97]
Mouse B6.1 cells IL-2 HDAC1d
Human acute promyelocytic leukaemia
NB4 cells
Arsenic trioxide CASPASE-10f Phos/AcH3 Ser10/Lys14 [88]
Human WI-38 ¢broblasts Arsenite c-fos, c-jun PhosH3 Ser10a, Phos/AcH3
Ser10/Lys14
[26]
Human HeLa cells Virus infection IFN-L promotere AcH4 Lys8, Lys12, AcH3 Lys9,
Lys14, PhosH3 Ser10a
[40]
Human glioblastoma T98G cells TPA and serum Collagenaseg PhosH3 Ser10, AcH3 Lys9 and/or
Lys14b, AcH4
[98]
Modi¢cations tabulated here are those for which a stimulus-induced increase was observed. Other modi¢cations may be present, but the levels
at speci¢c genes do not increase upon stimulation or were not assayed.
Abbreviations: EGF, epidermal growth factor; EAn, EGF/anisomycin; sAn, sub-inhibitory anisomycin; TPA, 12-O-tetradecanoylphorbol 13-
acetate; FSH, follicle-stimulating hormone; atRA, all-trans-retinoic acid; LPS, lipopolysaccharide; SGK, serum glucocorticoid kinase; MKP1,
mitogen-activated protein kinase phosphatase; IFN, interferon; IL, interleukin; MCP-1, macrophage chemoattractant protein-1.
aRecognition by this PhosH3 Ser10 antibody is not a¡ected by acetylation at Lys14.
bRecognition by this AcH3 Lys9 and/or Lys14 antibody is lost when serine 10 is phosphorylated [20]. This antibody has recently been shown
to be largely speci¢c for AcH3 Lys9 [83] although previous peptide competition experiments showed that the antibody was blocked in the pres-
ence of an AcH3 Lys14 peptide [19].
cHDAC1 is a late inducible gene. ChIP assays were after 3 h sAn and TSA (Trichostatin A) treatment.
dChIP assays were after 16 h IL-2 treatment.
eIFN-L mRNA is ¢rst detected 6 h after virus infection. H3 and H4 modi¢cations are ¢rst detected 2^3 h after virus infection.
fPeak induction for this gene was after 12 h treatment with arsenic trioxide. ChIP assays were after 48 h treatment.
gMethylation at H3 Lys4 was also observed at the collagenase promoter.
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fection of CLS ¢broblasts with RSK2 DNA restored the
EGF-stimulated phosphorylation of histone H3 [70]. Mitotic
H3 phosphorylation still occurred normally in these cells.
Based on these experiments, RSK2 was proposed as the li-
gand-stimulated H3 kinase. In the light of more recent experi-
ments, these conclusions, and indeed the use of CLS ¢bro-
blasts to derive kinase^substrate relationships, need to be
re-examined. Firstly, the de¢ciency for mitogen-stimulated
(EGF) CREB phosphorylation that was observed in CLS cells
has not been observed in recent studies with other mitogens
using mouse RSK2 knockout cells. In these cells platelet-de-
rived growth factor- and insulin-like growth factor-1-stimu-
lated CREB phosphorylation was una¡ected indicating no
requirement for RSK2 [71]. In addition, MSK1/2 has been
identi¢ed as the major mitogen/stress-induced CREB kinase(s)
from studies in MSK1 [72] and MSK1/2 knockout cells [73].
Furthermore, these authors were unable to reproduce the
EGF-stimulated CREB phosphorylation defect previously re-
ported in the CLS ¢broblasts [73]. It is unclear why there is a
di¡erence in signalling to CREB and ATF1 between the
RSK2 knockout and CLS cells. One possible explanation
may be additional uncharacterised mutations in other kinases
in the CLS cells, or that during their establishment in culture,
other kinases in CLS ¢broblasts have been a¡ected. Similar
problems have now arisen in respect of the reported histone
H3 phosphorylation defect in CLS ¢broblasts. Recent at-
tempts to reproduce these experiments have failed; a com-
pletely normal histone H3 phosphorylation response was
seen in CLS ¢broblasts, compromising the major piece of
reported evidence for RSK2/MAPKAP-K1b being the induc-
ible histone H3 kinase [56].
7. MSK1/2
MSK1/2 were identi¢ed by homology searching using the
MAPKAP-K1 N-terminal domain [74]. They are localised in
the nucleus, consistent with roles in generating nuclear re-
sponses, and are activated by both the ERK and p38 MAP
kinase pathways [74]. In vitro studies have shown that MSK1
phosphorylates H3 (and HMG-14) on the physiologically rel-
evant sites and with a much higher e⁄ciency than either
RSK1 or RSK2. Further, the small molecule inhibitor H89
inhibits MSK1/2 activity in vitro and inhibits the nucleosomal
response and IE gene induction elicited via both the ERK and
p38 MAP kinase pathways in vivo at concentrations at which
RSK1 and 2, MAP kinases and transcription factors are not
a¡ected [17]. From these studies MSK1 was identi¢ed as the
best candidate kinase for the phosphorylation of H3 and
HMG-14.
The most conclusive evidence for MSK1/2 as the H3/HMG-
14 kinase has emerged very recently. Studies in MSK1/2 sin-
gle- and double-knockout cells show that TPA- and anisomy-
cin-induced (as well as EGF- and UV-induced) histone H3
(and HMG-14) phosphorylation is severely reduced or abol-
ished, indicating that MSKs, particularly MSK2, are the ma-
jor H3 (and HMG-14) kinases activated by both mitogens and
stress [56]. The H3 phosphorylation defect is recoverable by
reintroduction of MSK2 by transfection into these cells.
8. Stimulus-induced histone H3 kinases in other organisms
Homologues of the downstream kinases MSK and RSK
have not been identi¢ed in Saccharomyces cerevisiae, although
equivalents of the ERK and p38 MAP kinases are present.
However, Snf1 has been identi¢ed as an H3 kinase responsible
for the inducible H3 Ser10 phosphorylation observed at the
activated INO1 gene in response to inositol deprivation in
yeast [51]. In Drosophila the JIL-1 kinase has been identi¢ed
as a homologue of MSK that localises speci¢cally to the gene
active interband regions of larval polytene chromosomes and
phosphorylates histone H3 in vitro [75] but this may be in-
volved in the maintenance of chromatin structure during in-
terphase rather than with inducible H3 phosphorylation [76].
Protein kinase A (PKA) has also been reported to be a
histone H3 kinase in rat ovarian granulosa cells [77]. H3 phos-
phorylation induced by follicle-stimulating hormone (FSH)
was not inhibited by pre-treatment with a variety of inhibitors
to various signalling pathways, including the ERK pathway
inhibitor PD098059 and the p38 pathway inhibitor SB203580
[77]. A dependence on PKA was determined by the reduction
in FSH-stimulated H3 phosphorylation when cells were pre-
treated with the PKA inhibitor protein peptide PKI attached
to the cell-permeabilising TAT peptide. PKA was also shown
to phosphorylate H3 directly in vitro [77]. However, the orig-
inal demonstration of PKA as an e⁄cient kinase for histone
H3 occurred during investigations on condensed mitotic chro-
mosomes [42,78], now thought to be mediated in vivo by
Aurora/Ipl kinases discussed above.
9. Does histone H3 phosphorylation direct its subsequent
acetylation to produce phosphoacetylation?
From the increasing number of chromatin immunoprecipi-
tation (ChIP) experiments with a variety of modi¢cation-spe-
ci¢c histone antibodies, the picture of inducible H3 phosphor-
ylation, acetylation and phosphoacetylation, targeted to (IE)/
inducible gene chromatin that is emerging is one of a complex
and dynamic pattern of multiple modi¢cations. Present indi-
cations are that phosphorylation occurs at Ser10, and lysines
9 and 14 are both acetylated, probably simultaneously [19,20]
(see Table 2). How both modi¢cations are targeted to the
same H3 tail and the functional interrelationship between
them remains unclear and is another area of controversy in
the literature. There are two possible mechanisms.
9.1. Synergistic coupled modi¢cations
One possibility is that the two modi¢cations are mechanis-
tically linked so that phosphorylation of H3 directs its subse-
quent acetylation. This is the coupled and synergistic model
that has been proposed to account for the EGF-stimulated
phosphorylation (Ser10) and acetylation (Lys14) observed at
the c-fos gene in mouse cells, [19] and the INO1 gene in yeast
cells [51]. The experiments in mouse cells are discussed further
below (Section 9.2). This model is based on the demonstration
in vitro that several recombinant HAT proteins, including the
prototypical Gcn5, preferentially acetylate an H3 peptide
phosphorylated at Ser10 compared with the equivalent un-
modi¢ed H3 tail peptide [19,79]. Furthermore, this preferen-
tial acetylation of the phosphopeptide, reportedly at Lys14,
was lost in a Gcn5 mutant with Arg164 changed to alanine, a
residue in close proximity to H3 Ser10 in the Gcn5/CoA/H3
peptide crystal structure [79]. In yeast, this sequential model
has been proposed for the phosphorylation and acetylation
observed at the INO1 gene, in response to inositol starvation,
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with Snf1 as the H3 kinase [51]. Using Ser10 mutant strains,
as well as Snf1- and Gcn5-de¢cient strains, Lys14 acetylation
by Gcn5 was shown to require phosphorylation at Ser10 [51].
Whether Gcn5 is responsible for the acetylation at H3 Lys14
is not entirely clear. Surprisingly, ChIP data for a number of
yeast promoters, including INO1, show that Gcn5 acetylates
all sites of H3 except Lys14 [80]. These experiments were done
using histone site-speci¢c acetyl-lysine antibodies that were
characterised by ChIP screening against speci¢c lysine substi-
tution mutations.
These studies have recently been advanced using a new
technique that allows these assays to be performed not just
on modi¢ed synthetic peptides, but on reconstituted nucleo-
somal arrays with predetermined histone tail modi¢cations
[81]. A peptide ligation strategy was used in which chemically
synthesised histone H3 N-terminal tail peptides with or with-
out phosphorylated Ser10 were ligated with the puri¢ed re-
combinant C-terminal domain of H3. Nucleosomal arrays
were then reconstituted using octamers containing the ligated
H3 molecules. These reconstituted arrays with phosphorylated
histone H3 were tested in HAT assays using Gcn5 alone or in
the native SAGA complex. Interestingly, while Gcn5 prefer-
entially acetylated H3 in the nucleosomal arrays reconstituted
with phosphorylated H3 in accord with studies described
above [19,51,79], Gcn5 in the SAGA complex showed no pref-
erence for phosphorylated H3 over non-phosphorylated H3 in
these arrays. Possible reasons for this di¡erence could be that
in the SAGA complex other subunits may in£uence the mode
of binding to the H3 tail. Also, there may be additional con-
tacts within the nucleosome, for example contacts with other
histone tails, that are not possible with peptide substrates [81].
Using this peptide ligation strategy it should be possible to
generate and analyse nucleosomal arrays containing single or
multiple post-translational modi¢cations, which should ad-
vance understanding of their possible functions.
9.2. Independent dynamic modi¢cations
A distinct model envisages that phosphorylation and acety-
lation are independently targeted to the same nucleosomes by
recruitment of the relevant enzyme complexes to regulatory
elements in the gene as opposed to the H3 tail itself, and that
the modi¢cations can coincide to produce phosphoacetylation
on H3 tails [20,31].
Work from our lab supports this second mechanism. Anti-
bodies that recognise mutually exclusive combinations of
modi¢cations were used to show that nucleosomes from the
same region of active IE gene chromatin exist in two forms at
the same time, a larger highly acetylated population that is
not phosphorylated and a smaller phosphoacetylated (Lys9/
Ser10) population. The existence of these two separate pop-
ulations indicates that prior phosphorylation is not obligately
required for acetylation. Furthermore, in support of the ‘syn-
ergistic and coupled’ model, it was previously claimed that the
inhibition of histone H3 phosphorylation using MAP kinase
inhibitors resulted in an inhibition of acetylation at IE genes
[19]. This has not proved reproducible despite being analysed
in the same cell type; experiments in our lab using several
stimuli and kinase inhibitors led to the opposite conclusion,
namely that inducible H3 acetylation at IE genes was normal
even when its phosphorylation was blocked [20]. This model
has received further support recently; in MSK1/2 knockout
cells, histone H3 phosphorylation at IE genes is severely re-
duced, whereas inducible acetylation at these genes is rela-
tively una¡ected [56]. A ¢nal piece of evidence in support of
independent dynamic modi¢cations comes from studies with
TSA, which showed that acetylation is continuously turning
over even in quiescent cells, indicating that HATs and
HDACs are already operating at IE genes, even in the absence
of MAP kinase activation or H3 phosphorylation. Hence, H3
phosphorylation is not required for targeted acetylation at
these genes [20].
The overwhelming indication from these studies is that in
mouse ¢broblasts, phosphorylation and acetylation are inde-
pendently delivered to histone H3 at IE genes and that these
modi¢cations are highly dynamic in nature and can coincide
to give rise to phosphoacetylation at a subset of tails.
A point worth mentioning here is that consideration of
antibody speci¢cities, a major complication in these studies,
is critical in the interpretation of all these experiments (dis-
cussed in [82]). For example, several studies have now shown
that the widely used commercially available anti-acH3 Lys9/
14 antibody is occluded by phosphorylation at Ser10 [20], a
complication that a¡ects some of the earlier studies using this
antibody [51]. Furthermore, it is now shown to be largely
speci¢c for H3 acetylated at Lys9 and not Lys14 [83] although
previous peptide competition experiments showed that this
antibody was blocked in the presence of an acH3 Lys14 pep-
tide [19].
10. MAP kinase-mediated acetylation of histones on inducible
genes
While the ERK and p38 pathways are clearly responsible
for delivering histone H3 phosphorylation, the nature of the
signal that causes enhanced acetylation at the same histone
tails is presently unclear. Intriguingly, a distinct MAP kinase
cascade, the JNK/SAPK cascade (see Fig. 1), has been iden-
ti¢ed as a potential mediator of this histone acetylation at IE
genes [35]. By microinjection experiments in serum-starved
NIH3T3 cells these authors found that activation of the chro-
mosomal c-fos gene or integrated serum response factor-con-
trolled reporter genes by a constitutively active form of the
small GTPase RhoA required activation of an additional sig-
nalling pathway (the JNK/SAPK pathway) that also induced
H4 acetylation at these genes. Thus, distinct MAP kinase
cascades may eventually turn out to converge on the same
histone H3 tail to elicit their multiple modi¢cation during
gene induction. This is an area of great current interest which
should be resolved in the near future.
11. Possible roles of inducible H3 phosphoacetylation in (IE)
gene transcription
Signal-induced phosphorylation of serine 10 and/or phos-
phoacetylation of histone H3 has now been observed in an
increasing number of systems, documented in Table 2. Al-
though a clear link between mitogen- or stress-inducible his-
tone H3 phosphorylation and gene transcription (and histone
H3 acetylation) is established, its precise molecular function
remains unclear and represents the next major challenge
in this area. When H3 (and HMG-14) phosphorylation is
blocked either by the treatment of cells with H89 [17] or in
MSK1/2 knockout cells [56] IE gene induction is not ablated
but the e⁄ciency of induction is a¡ected, altering their char-
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acteristic patterns of expression. This indicates that the nucle-
osomal response may not be essential for IE gene induction in
the same way as transcription factor phosphorylation [28,31],
but that it may in£uence the rate/pro¢le of expression of these
genes. One broad class of function would be that phosphor-
ylation mediates changes in nucleosome and chromatin struc-
ture by disrupting/altering histone^DNA charge interactions
facilitating easier access to the underlying DNA sequences by
transcription factors. This has been suggested for a subset of
stimulus-induced NF-UB-dependent cytokine and chemokine
genes in which p38-induced H3 phosphorylation was pro-
posed to enhance the accessibility of the NF-UB binding sites
[84]. A second function, more aligned with the histone code
hypothesis, is that the phosphoacetyl epitope on histone H3 at
Ser10 (as well as on Ser6 of HMG-14) serves as a binding
motif for recruitment of coactivator complexes such as HATs
or chromatin remodelling complexes, in the same way as is
already established for phosphorylated transcription factors at
upstream promoter sequences [85,86].
The fact that inducible H3 phosphoacetylation is a tightly
regulated process and occurs on only a small fraction of the
nucleosomes associated with IE genes is now well established
in the literature. Outstanding questions remain about the pre-
cise interplay of multiple modi¢cations, the mechanisms by
which the two enzyme systems are targeted to the same his-
tone H3 tail and perhaps most importantly, their precise mo-
lecular role in the process of IE gene induction.
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